Evidence map›Paper›PMID 36445624›Full record

Trial reportCardiovascular drugs and therapy2024

Safety and Efficacy of CYP2C19 Genotype-Guided Escalation of P2Y

Roy O Mathew, Mandeep S Sidhu, Charanjit S Rihal, Ryan Lennon, Mohammed El-Hajjar, Neil Yager, Radmila Lyubarova, Khaled Abdul-Nour, Steven Weitz, D Fearghas O'Cochlain and 10 more

Registry-linked trialOpen access · greenAbstract readRandomized Controlled TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cardiovascular drugs and therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01742117 (Tailored Antiplatelet Initiation to Lesson Outcomes Due to Decreased Clopidogrel Response After Percutaneous Coronary Intervention), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01742117 phase4completednot on this map

Tailored Antiplatelet Initiation to Lesson Outcomes Due to Decreased Clopidogrel Response After Percutaneous Coronary Intervention (TAILOR-PCI)

TypeinterventionalSponsorMayo ClinicRan2013 to 2020Enrolled5,276ConditionsCoronary Artery Disease, Acute Coronary Syndrome, StenosisArmsClopidogrel, Ticagrelor
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Review
  3. Circulation · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 13 institutions in 2 countries.

Roy O Mathew *Department of Medicine, Loma Linda VA Health Care System, 11201 Benton Street, Loma Linda, CA, 92357, USA. Roy.mathew@va.gov.
Mandeep S Sidhu *Department of Medicine, Albany Medical College, 43 New Scotland Avenue Albany, Schenectady, NY, 12208, USA. mssidhu@yahoo.com.ORCID 0000-0001-6440-8492
Charanjit S RihalDepartment of Medicine, Mayo Clinic, Rochester, MN, USA.
Ryan LennonDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.
Mohammed El-HajjarDepartment of Medicine, Albany Medical College, 43 New Scotland Avenue Albany, Schenectady, NY, 12208, USA.
Neil YagerDepartment of Medicine, Albany Medical College, 43 New Scotland Avenue Albany, Schenectady, NY, 12208, USA.
Radmila LyubarovaDepartment of Medicine, Albany Medical College, 43 New Scotland Avenue Albany, Schenectady, NY, 12208, USA.
Khaled Abdul-NourHenry Ford Health System, Detroit, MI, USA.
Steven WeitzCardiology Associates of Schenectady, Schenectady, NY, USA.
D Fearghas O'CochlainDepartment of Medicine, May Clinic Health System, Eau Claire, WI, USA.
Vishakantha MurthyDepartment of Endocrine and Cardiovascular Diseases, Mayo Clinic, Rochester, MN, USA.
Justin LevisayDepartment of Medicine, North Shore University Health System, Evanston, IL, USA.
Kevin MarzoDepartment of Medicine, Winthrop University Hospital, Mineola, NY, USA.
John GrahamDepartment of Medicine, St. Michael's Hospital, Toronto, ON, Canada.
Vlad DzavikDepartment of Medicine, University Health Network-Toronto General Hospital, Toronto, ON, Canada.
Derek SoDepartment of Medicine, University of Ottawa Heart Institute, Ottawa, ON, Canada.
Shaun GoodmanDepartment of Medicine, St. Michael's Hospital, Toronto, ON, Canada.
Yves D RosenbergNational Heart Lung and Blood Institute, Bethesda, MD, USA.
Naveen PereiraDepartment of Medicine, Mayo Clinic, Rochester, MN, USA.
Michael E FarkouhDepartment of Medicine, University Health Network-Toronto General Hospital, Toronto, ON, Canada.
Albany Medical Center Hospital · USMayo Clinic in Arizona · USSt. Michael's Hospital · CAUniversity Health Network · CAHenry Ford Health System · USMayo Clinic · USMayo Clinic Health System · USMayo Clinic in Florida · USNational Heart Lung and Blood Institute · USNorthShore University HealthSystem · USUniversity of Ottawa · CAVA Loma Linda Healthcare System · USWinthrop-University Hospital · US

Funding

TAILOR PCI: Transitioning a Genotype Based Randomized Clinical Trial to a Registry Using Digital SolutionsU01HL128606 · NHLBI · MAYO CLINIC ROCHESTER · PI FARKOUH, MICHAEL E, PEREIRA, NAVEEN LUKE · 2016 to 2019
$7.0M
Clinical Implementation of Clopidogrel Pharmacogenetics: The TAILOR-PCI Trial - DCCU01HL128626 · NHLBI · MAYO CLINIC ROCHESTER · PI BAILEY, KENT R · 2016 to 2019
$1.9M
NHLBI NIH HHS U01 HL128606NHLBI NIH HHS U01HL128606NHLBI NIH HHS U01 HL128626NHLBI NIH HHS U01HL128626
6 · The paper itself

Abstract

purposeChronic kidney disease (CKD) is a risk factor for ischemic and bleeding events with dual antiplatelet therapy after percutaneous coronary intervention (PCI). Whether the presence of CYP2C19 loss of function (LOF) alleles modifies this risk, and whether a genotype-guided (GG) escalation of P2Y

methodsThis was a post hoc analysis of randomized patients in TAILOR PCI. Patients were divided into two groups based on estimated glomerular filtration rate (eGFR) threshold of < 60 ml/min/1.73 m

resultsMean (standard deviation) eGFR among patients with CKD was 49.5 (8.4) ml/min/1.72 m

conclusionsIn this exploratory analysis, escalation of P2Y CLINICAL

trial registrationhttps://clinicaltrials.gov/ct2/show/NCT01742117?term=TAILOR-PCI&draw=2&rank=1 . NCT01742117.

Indexed as

Cytochrome P-450 CYP2C19Glomerular Filtration RatePercutaneous Coronary InterventionPlatelet Aggregation InhibitorsPurinergic P2Y Receptor AntagonistsRenal Insufficiency, ChronicAgedCoronary Artery DiseaseDual Anti-Platelet TherapyFemaleGenotypeHemorrhageHumansKidneyMaleMiddle AgedCYP2C19 protein, humanCytochrome P-450 CYP2C19Platelet Aggregation InhibitorsPurinergic P2Y Receptor AntagonistsAntiplatelet therapyChronic kidney diseaseCoronary artery diseaseCYP2C19Percutaneous coronary interventionPharmacogenomics

Identifiers

PMID36445624
PMCPMC10225474
OpenAlexW4310290800

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.